Related references
Note: Only part of the references are listed.Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response
Jose Luis Casado et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Raymond T. Chung et al.
HEPATOLOGY (2015)
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis
JOURNAL OF HEPATOLOGY (2015)
EASL Recommendations on Treatment of Hepatitis C 2015
JOURNAL OF HEPATOLOGY (2015)
Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis
Ehsaan Akhtar et al.
LIVER INTERNATIONAL (2015)
Evolution of Noninvasive Tests of Liver Fibrosis Is Associated With Prognosis in Patients With Chronic Hepatitis C
Julien Vergniol et al.
HEPATOLOGY (2014)
Risk factors for liver-related mortality in chronic hepatitis C patients: A deceased case-living control study
Qing-Lei Zeng et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
Thierry Poynard et al.
JOURNAL OF HEPATOLOGY (2013)
The diagnostic accuracy of Fibroscan® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response
Roberta D'Ambrosio et al.
JOURNAL OF HEPATOLOGY (2013)
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
Roberta D'Ambrosio et al.
HEPATOLOGY (2012)
APASL consensus statements and management algorithms for hepatitis C virus infection
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2012)
Excess Mortality in Patients with Advanced Chronic Hepatitis C Treated with Long-Term Peginterferon
Adrian M. Di Bisceglie et al.
HEPATOLOGY (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Histologic Outcomes in Hepatitis C-Infected Patients with Varying Degrees of Virologic Response to Interferon-Based Treatments
Paul J. Pockros et al.
HEPATOLOGY (2010)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis
G. T. Everson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Brief communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis C
Vincent Mallet et al.
ANNALS OF INTERNAL MEDICINE (2008)
Grading and staging systems for inflammation and fibrosis in chronic liver diseases
Zachary D. Goodman
JOURNAL OF HEPATOLOGY (2007)
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
Joseph F. Perz et al.
JOURNAL OF HEPATOLOGY (2006)
Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study
M Cornberg et al.
JOURNAL OF HEPATOLOGY (2006)
Reversibility of hepatitis C virus-related cirrhosis
S Pol et al.
HUMAN PATHOLOGY (2004)
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis
A Abergel et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2004)
Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1
LJ Jeffers et al.
HEPATOLOGY (2004)
Sampling variability of liver fibrosis in chronic hepatitis C
P Bedossa et al.
HEPATOLOGY (2003)
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin
T Poynard et al.
HEPATOLOGY (2003)
Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin
A Arif et al.
DIGESTIVE DISEASES AND SCIENCES (2003)
Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon
F Toccaceli et al.
JOURNAL OF VIRAL HEPATITIS (2003)
Progression of fibrosis in chronic hepatitis C
MG Ghany et al.
GASTROENTEROLOGY (2003)
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
T Poynard et al.
GASTROENTEROLOGY (2002)
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C
V de Lédinghen et al.
JOURNAL OF HEPATOLOGY (2002)
Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis
LM Fletcher et al.
GASTROENTEROLOGY (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
KL Lindsay et al.
HEPATOLOGY (2001)
Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha
V Leroy et al.
JOURNAL OF HEPATOLOGY (2001)
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
T Poynard et al.
HEPATOLOGY (2000)
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
Y Shiratori et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
